As of Nov 19, 2026, 0 of 1 active firms rate CLGN a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
CLGN EPS & revenue forecast
EPS · NEXT QUARTER
$-0.24
Range $-0.24 – $-0.24 · 1 analysts · -14% YoY
Next period, 1 analysts expect Collplant Biotechnologies Ltd to earn $-0.24 a share (range $-0.24 – $-0.24), versus $-0.28 a year earlier. Full-year consensus is $-0.59, growing to $-0.18 the year after.
REVENUE · NEXT QUARTER
—
Range — – — · 1 analysts
Revenue is expected to reach — (range — – —). Full-year consensus is $6.1M, rising to $7.6M next year.
Top analysts covering Collplant Biotechnologies Ltd
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on CLGN.
#1
Swayampakula Ramakanth
HC Wainwright & Co. · Rank #321
Buy
$11.00+223.5% to target
Overall win rate
38%
+ Follow
#2
Jason Kolbert
D. Boral Capital · Rank #562
Neutral
No targeton CLGN
Overall win rate
22%
+ Follow
CLGN stock forecast FAQ
What is CLGN's average 12-month price target?+
The 1 active firms with a live target average $12.00 for Collplant Biotechnologies Ltd over the next 12 months, ranging from a $12.00 high to a $12.00 low, as of Nov 19, 2026.
Is CLGN stock a Buy, Sell or Neutral right now?+
The current consensus is Insufficient coverage. Of the 1 active firms as of Nov 19, 2026, 0 rate it Buy or Strong Buy, 1 rate it Neutral, and 0 rate it Sell or Strong Sell.
How many active Wall Street firms cover CLGN?+
1 active firms have a recognized rating on Collplant Biotechnologies Ltd as of Nov 19, 2026, and 1 active firms carry a live 12-month price target.
Who is the most accurate analyst covering CLGN?+
Among analysts who currently cover CLGN, Swayampakula Ramakanth of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #321). Their current call is Buy with a $11.00 target.
What is Collplant Biotechnologies Ltd's projected EPS for next quarter?+
The consensus estimate is $-0.24 per share (range $-0.24 – $-0.24) across 1 analysts. Full-year EPS is projected at $-0.59, rising to $-0.18 the following year.
How much revenue is Collplant Biotechnologies Ltd expected to report next quarter?+
Consensus revenue is — (range — – —). Full-year revenue is projected at $6.1M, growing to $7.6M next year.
Have analysts been upgrading or downgrading CLGN lately?+
As of Nov 19, 2026, 0 of 1 active firms rate CLGN a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their CLGN calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.